Chipscreen sets high standard in Shanghai debut

Chipscreen’s robust debut could entice companies to choose a Shanghai listing over one in Hong Kong

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in Hong Kong.

Shares of Shenzhen Chipscreen Biosciences Ltd. (Shanghai:688321) rocketed through their first day of trading Monday to add about RMB37.4 billion ($4.2 billion) to the company’s market cap.

The stock opened trading up RMB104.57 (512%)

Read the full 714 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE